Optical Detection of Degraded Therapeutic Proteins

• Main Authors: Wu, Di (Author), Hancock, William (Author), Herrington, William F. (Contributor), Singh, Gajendra Pratap (Contributor), Barone, Paul (Contributor), Ram, Rajeev J (Contributor)
• Other Authors: Massachusetts Institute of Technology. Center for Biomedical Innovation (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Massachusetts Institute of Technology. Research Laboratory of Electronics (Contributor)
• Format: Article
• Language: English
• Published: Nature Publishing Group, 2018-05-02T19:14:42Z.
• Subjects: Article
• Online Access: Get fulltext

The quality of therapeutic proteins such as hormones, subunit and conjugate vaccines, and antibodies is critical to the safety and efficacy of modern medicine. Identifying malformed proteins at the point-of-care can prevent adverse immune reactions in patients; this is of special concern when there is an insecure supply chain resulting in the delivery of degraded, or even counterfeit, drug product. Identification of degraded protein, for example human growth hormone, is demonstrated by applying automated anomaly detection algorithms. Detection of the degraded protein differs from previous applications of machine-learning and classification to spectral analysis: only example spectra of genuine, high-quality drug products are used to construct the classifier. The algorithm is tested on Raman spectra acquired on protein dilutions typical of formulated drug product and at sample volumes of 25 μL, below the typical overfill (waste) volumes present in vials of injectable drug product. The algorithm is demonstrated to c orrectly classify anomalous recombinant human growth hormone (rhGH) with 92% sensitivity and 98% specificity even when the algorithm has only previously encountered high-quality drug product.
United States. Defense Advanced Research Projects Agency (Contract N66001-13-C-4025)